Dexcom Stock Dives Based on the strong first quarter, Dexcom now expects full-year sales to grow 17%-22% to $2.26 billion to $2.36 billion. Dexcom stock tumbled late Thursday even after the diabetes devices maker beat Wall Street's first-quarter expectations and raised full-year sales guidance. [Extracted from the article]
Copyright of Investors Business Daily is the property of Investor's Business Daily and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.
